These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 23722501)

  • 1. Long-term response of refractory primary cold agglutinin disease to eculizumab therapy.
    Gupta N; Wang ES
    Ann Hematol; 2014 Feb; 93(2):343-4. PubMed ID: 23722501
    [No Abstract]   [Full Text] [Related]  

  • 2. High efficacy of eculizumab treatment for fulminant hemolytic anemia in primary cold agglutinin disease.
    Makishima K; Obara N; Ishitsuka K; Sukegawa S; Suma S; Kiyoki Y; Baba N; Sakamoto T; Kato T; Kusakabe M; Nishikii H; Kurita N; Yokoyama Y; Sakata-Yanagimoto M; Hasegawa Y; Chiba S
    Ann Hematol; 2019 Apr; 98(4):1031-1032. PubMed ID: 30324459
    [No Abstract]   [Full Text] [Related]  

  • 3. Long-term efficacy of the complement inhibitor eculizumab in cold agglutinin disease.
    Röth A; Hüttmann A; Rother RP; Dührsen U; Philipp T
    Blood; 2009 Apr; 113(16):3885-6. PubMed ID: 19372265
    [No Abstract]   [Full Text] [Related]  

  • 4. Eculizumab in cold agglutinin disease (DECADE): an open-label, prospective, bicentric, nonrandomized phase 2 trial.
    Röth A; Bommer M; Hüttmann A; Herich-Terhürne D; Kuklik N; Rekowski J; Lenz V; Schrezenmeier H; Dührsen U
    Blood Adv; 2018 Oct; 2(19):2543-2549. PubMed ID: 30291112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylactic use of eculizumab during surgery in chronic cold agglutinin disease.
    Tjønnfjord E; Vengen ØA; Berentsen S; Tjønnfjord GE
    BMJ Case Rep; 2017 May; 2017():. PubMed ID: 28487302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Refractory warm IgM-mediated autoimmune hemolytic anemia associated with Churg-Strauss syndrome responsive to eculizumab and rituximab.
    Chao MP; Hong J; Kunder C; Lester L; Schrier SL; Majeti R
    Am J Hematol; 2015 Jan; 90(1):78-81. PubMed ID: 24942207
    [No Abstract]   [Full Text] [Related]  

  • 7. Eculizumab, a real-life successful treatment for refractory cold agglutinin-mediated auto-immune hemolytic anemia secondary to lymphoproliferative disorders.
    Herbreteau L; Le Calloch R; Arnaud B; Cassou N; Rizcallah MJ; Hutin P; Le Clech L
    Ann Hematol; 2021 Aug; 100(8):2105-2106. PubMed ID: 34003325
    [No Abstract]   [Full Text] [Related]  

  • 8. Severe hemolytic anemia due to cold agglutinin complicating untreated chronic hepatitis C: efficacy and safety of anti-CD20 (rituximab) treatment.
    Etienne A; Gayet S; Vidal F; Poullin P; Brunet C; Harlé JR; Kaplanski G
    Am J Hematol; 2004 Apr; 75(4):243-5. PubMed ID: 15054819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Efficacity of rituximab in hemolytic anemia with cold autoantibodies case].
    Sekkach Y; Hammi S; Elqatni M; Fatihi J; Elomri N; Mekouar F; Badaoui M; Jira M; Smaali J; El Khattabi A; Amezyane T; Abouzahir A; Ghafir D
    Ann Pharm Fr; 2011 Jul; 69(4):205-8. PubMed ID: 21840439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful rituximab therapy in the treatment of refractory cold haemagglutinin disease with long-term disease control.
    Khalafallah A; Vos LJ; Beamish M; Rooney K
    Intern Med J; 2010 May; 40(5):387-9. PubMed ID: 20575998
    [No Abstract]   [Full Text] [Related]  

  • 11. Successful treatment of systemic lupus erythematosus-related refractory autoimmune hemolytic anemia with ofatumumab.
    Poulet A; Jarrot PA; Mazodier K; Jean R; Kaplanski G
    Lupus; 2019 Dec; 28(14):1735-1736. PubMed ID: 31610746
    [No Abstract]   [Full Text] [Related]  

  • 12. Drugs that inhibit complement.
    Schrezenmeier H; Höchsmann B
    Transfus Apher Sci; 2012 Feb; 46(1):87-92. PubMed ID: 22169380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cold agglutinin disease.
    Röth A; Dührsen U
    Eur J Haematol; 2010 Jan; 84(1):91. PubMed ID: 19614954
    [No Abstract]   [Full Text] [Related]  

  • 14. [Delayed response to rituximab of cold agglutinin haemolytic disease].
    Calvo-Villas JM; Cuesta Tovar J; Carreter de Granda E; Sicilia Guillén F
    An Med Interna; 2006 May; 23(5):224-8. PubMed ID: 16817700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of severe refractory autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab (humanized CD52 monoclonal antibody).
    Karlsson C; Hansson L; Celsing F; Lundin J
    Leukemia; 2007 Mar; 21(3):511-4. PubMed ID: 17215854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Efficacy of danazol in autoimmune hemolytic anemia with cold agglutinins. 4 cases].
    Geffray E; Najman A
    Presse Med; 1992 Sep; 21(31):1472-5. PubMed ID: 1465365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cold agglutinin disease secondary to severe SARS-CoV-2 treated with eculizumab.
    Dawudi Y; Federici L; Debus J; Zucman N
    BMJ Case Rep; 2022 Apr; 15(4):. PubMed ID: 35487646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Severe refractory idiopathic warm autoimmune haemolytic anaemia responsive to complement inhibition with eculizumab.
    Neave L; Wilson AJ; Lissack M; Scully M
    BMJ Case Rep; 2018 Dec; 11(1):. PubMed ID: 30567234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia.
    Zaja F; Iacona I; Masolini P; Russo D; Sperotto A; Prosdocimo S; Patriarca F; de Vita S; Regazzi M; Baccarani M; Fanin R
    Haematologica; 2002 Feb; 87(2):189-95. PubMed ID: 11836170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Autoimmune hemolytic anemia].
    Berentsen S; Sundic T; Hervig T; Tjønnfjord GE
    Tidsskr Nor Laegeforen; 2009 Nov; 129(21):2226-31. PubMed ID: 19898570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.